U.S. Commercialization Insights
Written for global manufacturers entering the United States and emerging U.S. biopharma teams building commercial infrastructure for the first time. Research is cited, limits are stated, and the human consequences stay visible.
What first-time U.S. launchers often discover too late—and the decisions that should be made before one approval date becomes the only date anyone can see.
By Sharon Lee
Founding Member · Upper Echelon Management
A practical way to decide what to build, what to buy, what to rent, and what not to fund yet.
By Sharon Lee
Founding Member · Upper Echelon Management
What the distance between FDA approval and patient access teaches first-time U.S. launchers.
By Sharon Lee
Founding Member · Upper Echelon Management
Why we publish
UEM publishes to help commercial leaders see decisions, dependencies, and evidence gaps earlier. Each article connects practical launch questions with the operating principles behind UEM and LaunchOS.
“The most useful answer is sometimes a clearer question, a visible assumption, or an honest statement that the evidence is not ready.”
Sharon Lee · Founding Member